Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study Finds Heart Device Trials Male-Dominated; FDA Promises Guidance

This article was originally published in The Gray Sheet

Executive Summary

Women remain underrepresented in pivotal studies of cardiac devices submitted to FDA, and there is a lack of analysis distinguishing between trial outcomes in men and women, researchers conclude in a study published online March 1.

You may also be interested in...



CDRH Launches ‘Health Of Women’ Program; Research Agenda To Focus On Ortho, Cardio Devices

The device center plans to develop a research roadmap to explore sex-based differences in outcomes to musculoskeletal and cardiovascular disease devices, as well as devices targeting diseases specific to women. CDRH launched the effort as part of its new “Health of Women” initiative at a June 24-25 workshop.

CDRH Launches ‘Health Of Women’ Program; Research Agenda To Focus On Ortho, Cardio Devices

The device center plans to develop a research roadmap to explore sex-based differences in outcomes to musculoskeletal and cardiovascular disease devices, as well as devices targeting diseases specific to women. CDRH launched the effort as part of its new “Health of Women” initiative at a workshop last week.

Need More Women For Device Trials? Create Better Consent Forms, FDA Says

Enrolling women and minorities in device trials remains a challenge. One potential solution highlighted at a recent FDA meeting: improve communication of potential treatment risks.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel